Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Florence Themenbrowser · Onkologie · Seite 64

Was ist neu im Gesundheitswesen?

Entdecken Sie tatsächlich neu veröffentlichte Arbeiten aus Medizin, Pflege, Therapie, Public Health und Life Sciences. Sortiert nach Publikationsdatum, nicht nach Zitierhäufigkeit.

Themen erkunden

Aktuelle Forschung nach Fachgebiet

24 neue Nachweise auf dieser Seite Publiziert in den letzten 30 Tagen Neueste zuerst Crossref DOI
24.08.2026journal-article

Cancer Research Communications

A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

Atish D. Choudhury, Caiwei Zhong, Wanling Xie, Bose S. Kochupurakkal, Peter I-Fan. Wu, Irbaz Bin. Riaz, Ruolin Liu, David D. Yang, Edmund Folefac, Daniel Lee, Mamta Parikh, David J. Einstein, Elizabeth R. Kessler, Tina Mayer, Rana R. McKay, Amanda Pace, Kent W. Mouw, Li Chen, Viktor A. Adalsteinsson, Eliezer M. Van Allen, Charles A. Kunos, Steven D. Gore, Biswajit Das, Alan D'Andrea, Mary-Ellen Taplin, Geoffrey I. Shapiro

Abstract Purpose: Inhibitors of the Ataxia telangiectasia and Rad3-related (ATR) protein kinase, a critical component of the DNA damage repair response, have synergistic anti-cancer activity with platinum compounds in preclinical models. We therefore conducted a Phase 2 study of the ATR inhibitor berzosertib+carboplatin vs. docetaxel+carboplatin in metastatic castration-resistant prostate cancer. Patients and Methods: Patients previously treated with at least one androgen receptor pathway inhibitor and taxane under …

24.08.2026journal-article

International Journal of Biology and Life Sciences

The Application of Gut Microbiota in the Diagnosis, Prognosis and Treatment of Colorectal Cancer

Jingyi Sun

The gut microbiota plays a significant role in the occurrence and development of colorectal cancer (CRC), and its application value in the diagnosis and treatment of CRC has received extensive attention in recent years. The gut microbiota has shown great potential as a non-invasive biomarker and therapeutic target in CRC. However, existing reviews mostly focus on mechanism descriptions and lack systematic analysis of clinical translation barriers. This article focuses on CRC and systematically reviews the research …

24.08.2026journal-article

Frontiers in Oncology

Deep learning-based cross-attention fusion of multimodal MRI for survival prediction and risk stratification in IDH-wildtype glioblastoma: a multicenter study

Shichao Liu, Risheng Liang

Background Glioblastoma (GBM) exhibits profound molecular and spatial heterogeneity, complicating prognostic evaluations. While multiparametric MRI provides crucial multidimensional biological information, conventional end-to-end deep learning integration strategies, such as early or late fusion, often fail to capture complex nonlinear cross-modal interactions. We aimed to systematically evaluate a cross-attention fusion (CAF) architecture for GBM survival prediction and quantify its incremental prognostic value re …

24.08.2026journal-article

World Journal of Clinical Oncology

Segment-specific patterns of regional lymph-node metastasis in primary small-cell carcinoma of the esophagus: A systematic review and meta-analysis

Ke-Xun Li, Jie Mao, Jian-Zhe Zhang, Zi-Long Qian, Yong-Tao Han, Xue-Feng Leng

BACKGROUND Primary small-cell carcinoma of the esophagus (SCCE) is a rare, biologically aggressive malignancy with a marked propensity for lymphatic dissemination. We estimated the prevalence of pathologically confirmed lymph-node metastasis in surgically staged SCCE and mapped the available segment-specific evidence at the nodal-station level. AIM To estimate the patient-level prevalence of pathologic lymph-node metastasis in surgically staged SCCE and to map the available segment-specific evidence at the station …

24.08.2026journal-article

Frontiers in Oncology

A pretreatment multiphasic CT-based decision-support model for differentiating pediatric hepatoblastoma from focal nodular hyperplasia

Lizhu Cai, Yun Peng

Background Hepatoblastoma (HB) and focal nodular hyperplasia (FNH) require markedly different management strategies in children, but differentiation can be challenging when multiphasic computed tomography (CT) findings are atypical or overlapping. This study aimed to develop and temporally validate a pretreatment multiphasic CT-based fusion model combining deep learning (DL) predictions with quantitative enhancement features for pediatric HB–FNH differentiation and to evaluate the potential value of model assistanc …

24.08.2026journal-article

Journal of Medicine, Nursing and Public health

Prevalence of Hyperglycemia and Its Association with Breast Cancer Stage: A Case-Control Study in Meru County, Kenya

Herbert W. Kibebe, Eric M. Muchiri, Maryjoy Kaimuri

Background: Hyperglycemia, a hallmark of type 2 diabetes mellitus (T2DM), is increasingly implicated in breast cancer pathogenesis through the Warburg effect, hyperinsulinemia, and chronic inflammation. Understanding its prevalence and relationship with breast cancer stage in Sub-Saharan African populations remains critical for informing context-specific screening strategies. Objectives: (1) To determine the prevalence of hyperglycemia (HbA1c ≥6.5%) among breast cancer patients compared to controls; and (2) to iden …

24.08.2026journal-article

mSystems

Integrative microbiome–methylome analysis links bacterial taxa to colorectal cancer histological subtypes

Ángel Escudero-Jiménez, Jorge Galán-Ros, Francisco Huertas-López, Andrea Pérez-Sarabia, Diogo Ribeiro, Fátima Postigo-Corrales, Ana Albaladejo-González, María Isabel Díaz-López, María Dolores López-Abellán, José García-Rodríguez, María Asunción Beltrán-Videla, Ana Belén Arroyo, Ana María Hurtado López, Ana Tapia-Abellán, Rubén Corral San Miguel, Edith Rodríguez-Braun, Eduardo Feliciangeli, Alberto Sánchez-Espinosa, Ana Conesa, Ginés Luengo-Gil, Pablo Conesa-Zamora

ABSTRACT Colorectal cancer (CRC) arises through distinct molecular and histological routes that may be shaped by interactions between the mucosa-associated microbiota and host epigenetic regulation. We analyzed paired tumor and adjacent non-tumor colorectal mucosa from CRC patients stratified by histological subtype (conventional vs serrated-pathway groups). Microbiota composition was profiled by Illumina sequencing, and host DNA methylation was assessed using genome-wide CpG arrays with targeted validation. Alpha …

24.08.2026journal-article

Journal of Trauma and Acute Care Surgery

A multicenter retrospective evaluation of treatment variation in patients with a blunt traumatic pneumothorax; noninvasive treatment versus tube thoracostomy (CONSTRAIN-Retro)

Angela Hartman, Leonie Vellekoop, Céline H. Van Delft, Michael H.J. Verhofstad, Ninos Ayez, Esther M.M. Van Lieshout, Mathieu M.E. Wijffels, CONSTRAIN study group,

BACKGROUND: There is no clear consensus to which extent noninvasive treatment can be used with regard to posttraumatic pneumothorax size. This results in treatment variation among physicians. This study primarily aimed to examine the current treatment variation in the management of unilateral pneumothorax after blunt trauma, varying in size. Secondarily, clinical outcomes were evaluated in patients with the greatest treatment variation. METHODS: This multicenter retrospective cohort study included adult patients ad …

24.08.2026journal-article

Frontiers in Oncology

From data silos to integrated diagnosis: multimodal machine learning in glioblastoma

Amin Zadeh-Shirazi, Bryan W. Day, Hui K. Gan, Guillermo A. Gomez

Effective glioblastoma care requires integrating multiparametric longitudinal MRI with histopathology, molecular profiling, and clinical records documenting surgery, radiotherapy, chemotherapy, and supportive treatments. In routine practice, however, these data streams are often evaluated separately rather than jointly, which can delay molecularly informed stratification, limit reproducibility across centers, and complicate interpretation of post-treatment imaging changes. Multimodal machine learning (MML) provides …

24.08.2026journal-article

Journal of Neuro-Oncology

Machine learning for functional outcome prediction after vestibular schwannoma surgery: a systematic review and diagnostic test accuracy meta-analysis

Shiva A. Nischal, Shaan Patel, Musa China, Kush M. Kale, Yi Hein Chai, Santosh Guru, William R. Muirhead, Patrick Grover

Abstract Purpose Machine learning (ML) models have been increasingly applied to predict postoperative facial nerve dysfunction and hearing preservation after vestibular schwannoma (VS) surgery. However, reported performance varies substantially, and the overall diagnostic accuracy and clinical reliability of these models remain uncertain. We conducted a systematic review and diagnostic test accuracy meta-analysis to characterise the current state and methodological readiness of ML-based prediction of these outcomes …

24.08.2026journal-article

Oncology, Nuclear Medicine and Transplantology

CRISPR Functional Genomics in Precision Oncology: Integrating Single-Cell Multi-Omics for Cancer Vulnerability Discovery

Olaitan Ebenezer Oluwadare, Meveilleoux Soronuchi Frankpeace, Oluwabukunmi M Oluwaniran, Jane Ifeyinwa Anatuanya, Lydia Amarachi Onwuemelem

Precision oncology seeks to identify patient-specific therapeutic vulnerabilities; however, conventional genomic profiling is limited by intratumoral heterogeneity and its inability to distinguish functional driver alterations from passenger mutations, often resulting in incomplete prediction of therapeutic response. Recently, the combination of CRISPR functional genomics with single-cell multi-omics has proven to be a paradigm-shifting strategy for understanding context-specific cancer vulnerabilities by causal fu …

24.08.2026journal-article

World Journal of Clinical Oncology

Congenital dermatofibrosarcoma protuberans in a seven-month-old infant initially misdiagnosed as infantile myofibroma: A case report

Chen-Jun Zheng, Chen-Liang Wan, Chuan-Bo Zhang, Bo Hai, Chun-Feng Huang

BACKGROUND Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive cutaneous sarcoma predominantly observed in adults 30 years to 50 years of age. It is exceedingly rare in infants and is often misdiagnosed owing to its indolent growth and resemblance to benign lesions such as hemangiomas or fibromas. CASE SUMMARY A 7-month-old male infant presented with a congenital dorsal mass that had gradually enlarged since birth. Initial biopsy of the lesion resulted in a misdiagnosis of infantile myofibroma. Giv …

24.08.2026journal-article

World Journal of Clinical Oncology

Letter to the Editor: Role of perioperative carcinoembryonic Antigen in guiding adjuvant chemotherapy for colorectal cancer

Wen-Ting Zheng, Guang-Yao Li

Du et al reported that postoperative carcinoembryonic antigen (CEA) may serve as a cost-effective marker to guide adjuvant chemotherapy in colorectal cancer. Although this study provides clinically relevant findings, several issues need further discussion. First, the retrospective design limits causal interpretation and remains susceptible to selection bias and unmeasured confounding, particularly in non-randomized treatment allocation. Second, the definition and timing of postoperative CEA measurement may influenc …

24.08.2026journal-article

CVIR Oncology

A cumulative cold dosimetry model for cryoablation: from geometry to dose-time planning

Francois H. Cornelis, Arthur A. Cornelis, Stephen B. Solomon

Abstract Purpose To propose a cumulative cold dose (CCD) model integrating spatial, temporal, and biological dosimetry for cryoablation protocol optimization. Methods Systematic searches identified studies reporting freeze duration effects, cell-type-specific lethal thresholds, lethal isotherm ratio, or protocol-stratified outcomes. CCD was defined as the total time tissue is held at or below its cell-type-specific lethal threshold across all freeze cycles, targeting ≥ 80% cell death probability per point. Isotherm …

24.08.2026journal-article

Cancer Research

Oncogenic KRAS Rewires mRNA Stability and Translation through AGO2-Mediated Disruption of the miRNA pathway

Ziyue Z. Yang, Angelina S. Bortoletto, Mara G. Cardenas, Mason D. Bartels, Savannah Mwesigwa, Charlotte A. Le Roux, Caroline G. Snider, Man-Tzu Wang, Huihui Fan, Eric L. Van Nostrand, Frank McCormick, Ronald J. Parchem

Abstract KRAS mutations occur in over 90% of pancreatic ductal adenocarcinomas (PDACs). Despite recent advances in targeting oncogenic KRAS, tumors eventually acquire resistance. A more comprehensive understanding of the mechanisms connecting KRAS signaling to tumor progression could facilitate the development of effective therapies to improve the treatment of KRAS-driven malignancies. Here, we dissected how oncogenic KRAS reprograms post-transcriptional regulation in PDAC. Oncogenic KRAS altered AGO2 phosphorylati …

24.08.2026journal-article

Revista Sustinere

Perfil clínico e epidemiológico de pacientes submetidas ao tratamento quimioterápico neoadjuvante de neoplasia da mama

Luiza Darla Aguiar Silva Paiva, João Paulo da Silva, Cleverson Felipe da Silva Ferreira

O câncer de mama é o segundo tipo de neoplasia mais frequente em mulheres no Brasil, ficando atrás apenas do câncer de pele não melanoma. A transformação de células normais em tumorais pode acontecer por mutações espontâneas ou induzidas, deficiência imunológica ou exposição a agentes carcinogênicos. O presente estudo tem como objetivo caracterizar o perfil clínico, os dados anatomopatológicos e imuno-histoquímicos de pacientes com neoplasia da mama em regime de quimioterapia neoadjuvante. Trata-se de um estudo obs …

24.08.2026journal-article

Clinical Nuclear Medicine

Comparison of the Prognostic Value of PET Metabolic Parameters and Postoperative Pathologic Response After Neoadjuvant Immunochemotherapy in Non–Small Cell Lung Cancer

You Cheng, Tian Qin, Fan Yang, Kaiyu Lu, Haoyu Zhu, Dan Shao

Objective: This study aimed to evaluate the prognostic value of serial PET/CT metabolic parameters and postoperative pathologic response separately, compare their predictive performance, and further assess their combined prognostic value in patients with non–small cell lung cancer (NSCLC) undergoing neoadjuvant immunotherapy plus chemotherapy. Methods: We retrospectively analyzed 219 NSCLC patients who received neoadjuvant immunotherapy plus chemotherapy, followed by surgery. Pre- and post-treatment PET/CT metaboli …

24.08.2026journal-article

Journal of Gerontology and Geriatrics

Sarcopenia as a Disorder of Skeletal Muscle Homeostasis: A Five-Pillar Translational Framework Linking Mechanisms, Diagnosis, and Treatment

Emilia Glowczewska-Siedlecka, Malgorzata Szafranska, Agata Doligalska-Dolina, Marcin Dolina, Amanda Zon, Marcelina Pekala, Michal Skowronski, Krzysztof Palgan, Katarzyna Napiorkowska-Baran

Sarcopenia is a progressive skeletal muscle disorder in which clinically relevant muscle failure is expressed primarily as reduced muscle strength, with low muscle quantity or quality used to confirm the diagnosis and impaired physical performance indicating greater severity in the EWGSOP2 (European Working Group on Sarcopenia in Older People 2) framework. This narrative review first defines the clinical phenotype and its current diagnostic operationalization and then uses an author-proposed five-pillar framework: …

24.08.2026journal-article

Life

Impact of Provider Volume on Intraprocedural Rupture Risk During Endovascular Treatment of Ruptured Intracranial Aneurysms: A Systematic Review and Meta-Analysis

Chao-Ya Yang, Kuo-Wei Chen, Fon-Yih Tsuang, Furen Xiao, Chung Liang Chai

Intraprocedural rupture (IPR) during coiling of ruptured intracranial aneurysms is a serious complication. In this study, we assessed whether center volume influences the risk of IPR. For this purpose, we conducted a systematic review (1996–present) including a final total of 98 studies. Centers were classified as high-volume (≥20 cases/year) or low-volume (<20), with the IPR rate as the primary outcome, and subgroup analyses by vascular territory and meta-regression were performed to quantify volume effects. The I …

24.08.2026journal-article

Vigilância Sanitária em Debate

Gerenciamento de riscos nas compras públicas de medicamentos oncológicos: estratégia e métodos para mitigação de falhas

Virginia Luiz de Sousa, Jorge Carlos Santos da Costa, Elezer Monte Blanco Lemes

Introduction: Public procurement of oncology medicines represents a significant share of healthcare expenditures and plays a crucial role in ensuring universal access to essential therapies. However, the bidding process is subject to failures that compromise efficiency, transparency, and patient safety. Objectives: To develop and apply a risk management (RM) model adapted to the reality of public procurement of oncology medicines, based on nationally and internationally recognized methodologies. Method: Case study …

24.08.2026journal-article

Clinical Cancer Research

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Hope S. Rugo, Sara M. Tolaney, Nancy Chan, Giuliano Borges, Rinat Yerushalmi, Marina N. Sharifi, Wassim McHayleh, Thaddeus Beck, Neelima Vidula, Erika Hamilton, Kristine J. Rinn, Joyce O'Shaughnessy, Giuseppe Curigliano, Javier Cortés, Isabel Garcia-Fructuoso, Philippe Aftimos, Begoña Bermejo de las Heras, Pablo Tolosa, Yuan Yuan, Vicente Valero, Marla Lipsyc-Sharf, Paula Muñoz Romero, Faten Koraichi Auriol, Alessandro Paoli, Jennifer A. Crozier, Tomer Wasserman, Virginia Kaklamani

Abstract Purpose: Treatment options for progression on first-line endocrine therapy (ET)+CDK4/6i for ER-positive/HER2-negative (ER+/HER2-) advanced breast cancer (ABC) include ET plus targeted agents (CDK4/6i or PI3K/AKT/mTOR-pathway inhibitors). Elacestrant is the first single-agent oral SERD that significantly improved progression-free survival (PFS) versus standard-of-care ET in ESR1-mutated and overall ER+/HER2- ABC populations. Patients and Methods: This phase 1b/2, umbrella trial enrolled patients with ER+/HE …

24.08.2026journal-article

Clinical Cancer Research

EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer From a Phase Ib/II, Open-Label, Multicenter Study

Ting Xu, Christine M. Parseghian, Yanqiao Zhang, Zhiyu Chen, Yanru Qin, Weisheng Zhang, Yanhong Deng, Hongming Pan, Shanzhi Gu, Changzheng Li, Fang Ren, Ying Wu, Qiaoyang Lu, Mingfei Zhang, Rong Wang, Yonghong Zhu, Lin Shen, Jian Li

Abstract Purpose EMB-01 is a novel EGFR × c-MET bispecific antibody. The phase Ib/II study (NCT05176665) presents the safety and antitumor activity of EMB-01 in patients predominantly with heavily pretreated metastatic colorectal cancer (mCRC). Patients and methods EMB-01 was administered at 1600 mg intravenously weekly. Primary endpoints were safety and tolerability in phase Ib, and antitumor activity in phase II. Secondary endpoints included cross-phase validation of antitumor activity and safety. Exploratory end …

24.08.2026journal-article

Advanced Science

AI‐Assisted Tumor Boundary Delineation via Targeted Ultrasmall Iron Oxide Nanoprobe for High‐Contrast HER2‐Positive Tumor Imaging

Jiaying Zheng, Yi Zhu, Xinrui Li, Sunxian Dai, Xiangyuan Ma, Hongwei Lu, Zhongling Wang, Benqing Zhou

ABSTRACT Breast cancer continues to be a leading cause of cancer‐related mortality in women globally, where precise diagnosis and clear tumor demarcation are critical for effective treatment. Herein, we developed a strategic platform that combines a novel ultrasensitive magnetic resonance (MR) contrast agent with deep learning to significantly enhance the tumor‐to‐normal ratio (TNR). We designed ultrasmall iron oxide nanoparticles (USIO NPs) conjugated with trastuzumab (Tmab) for targeted MR imaging of HER2‐positiv …

24.08.2026journal-article

Melanoma Research

Treatment discontinuation after complete response to BRAF/MEK inhibition in metastatic melanoma: long-term clinical outcomes from a single institution

Maja Ivanova, Igor Stojkovski, Violeta Klisarovska

The optimal duration of BRAF/MEK inhibitor therapy in patients with metastatic melanoma who achieve complete response remains uncertain. Although targeted therapy is commonly continued until disease progression or unacceptable toxicity, prolonged treatment may be associated with chronic adverse events, impaired quality of life, and treatment fatigue. We performed a retrospective single-center analysis of patients with BRAF -mutated metastatic melanoma who achieved radiologically confirmed complete response during c …